Study: inclisiran could prevent thousands of heart attacks in the US
NCT ID NCT07214857
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 30 times
Summary
This study used national health data to estimate how many US adults might be eligible for a new cholesterol-lowering drug called inclisiran. Researchers looked at people with high cholesterol despite taking statins and calculated how many heart attacks and strokes could be prevented over 10 years. The study did not test the drug itself but used existing data to predict its potential impact.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis
East Hanover, New Jersey, 07936, United States
Conditions
Explore the condition pages connected to this study.